News
Patient with and without diabetes who received patiromer were more likely to remain on spironolactone at 12 weeks compared with those who received placebo, a subgroup analysis of the AMBER trial showed.
News
The new packaging allows for ease of administration and convenience.
News
Investigators reviewed 13 trials of spironolactone and 1 trial of eplerenone.
News
Evidence in favor of SGLT2 inhibitors and nonsteroidal mineralocorticoid receptor antagonists for treating patients with diabetic kidney disease is growing.
News
Despite an increasing emphasis on HFmrEF over the past several years, there is a lack of authoritative guidance surrounding therapeutic approaches for these patients.
